INDOCO2023-04-012023-06-30 INDOCO2023-04-012023-06-30in-bse-fin:OneOperatingExpenses01Member INDOCO2023-04-012023-06-30in-bse-fin:OneOperatingExpenses02Member INDOCO2023-06-30 INDOCO2023-04-012023-06-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 532612 INDOCO NOTLISTED Indoco Remedies Limited Equity 2023-04-01 2024-03-31 2023-07-25 2023-07-14 INR Lakhs First quarter 10:30:00 11:30:00 2023-07-25 2023-07-25 Not applicable Single segment PHARMACEUTICALS 2023-04-01 2023-06-30 Unaudited Consolidated 4265000000.00 4100000.00 4269100000.00 1029700000.00 321300000.00 -64200000.00 915400000.00 77900000.00 198800000.00 1451100000.00 3930000000.00 339100000.00 0.00 339100000.00 85500000.00 11800000.00 97300000.00 0.00 241800000.00 0.00 0.00 0.00 0.00 241800000.00 -2300000.00 239500000.00 243900000.00 -2100000.00 241600000.00 -2100000.00 184300000.00 2 2.62 2.62 0.00 0.00 2.62 2.62 1. The unaudited Consolidated Results for the Quarter ended 30th June, 2023 have been reviewed by the Audit committee and approved by the Board of Directors of the Company at its meeting held on 25th July, 2023. The Statutory Auditors have expressed an Unmodified Audit opinion on these unaudited Consolidated Financial Results 2. The figures for corresponding previous periods have been restated / regrouped wherever necessary, to make them comparable. 3. The company has only one primary reportable segment of activity, namely, Pharmaceuticals. 4. Net Sales and Income from Operations as per Secondary Segment (Geographical) is as follows: Net Sales Quarter ended Quarter ended Quarter ended Year ended and Income 30.06.2023 31.03.2023 30.06.2022 31.03.2023 from (Unaudited) (Audited) (Unaudited) (Audited) Operations --------------------------------------------------------------------------------------------------------------------------- India 23,417 20,298 20,698 84,979 Outside India 18,264 22,577 18,823 79,026 Total 41,681 42,875 39,521 1,64,005 ============================================================ 5. The Consolidated Financial Results includes the Results of the following Companies; Name of the Company % of shareholding Consolidated as Xtend Industrial Designers & Engineers Pvt Ltd 100.00 Subsidiary Indoco Remedies Czech SRO 100.00 Subsidiary Indoco Remedies UK Ltd 100.00 Subsidiary Warren Remedies Private Limited 100.00 Subsidiary FPP Holding Company, LLC 85.00 Subsidiary -------------------------------------------------------------------------------------------------------------------------------- 6. The statutory auditors of the company have carried out limited review of the financial results for the quarter ended 30th June, 2023. 7. Figures for the quarter ended 31.3.2023 represents the difference between audited figures in respect of the full financial year and published figures for the period ended 31.12.2022 (limited reviewed). 8. The Company has acquired 85% equity stake in FPP Holding Company, LLC ( FPP Holding ) a company registered in Delaware, USA on 05th June, 2023 from Contract Pharmacal Corp for the aggregate consideration of USD 4 Million, thereby it becoming the subsidiary of the Company. Consequent to this acquisition, Florida Pharmaceutical Products, LLC ( FPP ) a wholly owned subsidiary of FPP Holding has become a step down subsidiary of the Company. FPP Holding through FPP is engaged in the business of distribution and marketing of the pharmaceutical products in USA. 9. There are no Exceptional Items OTHER EXPENSES 1212300000.00 RESEARCH & DEVELOPMENT EXPENSES 238800000.00 ITEMS THAT WILL NOT BE RECLASSIFIED TO PROFIT AND LOSS -3000000.00 -3000000.00 -700000.00 0.00